Vildagliptin: a new oral treatment for type 2 diabetes mellitus
Dose-ranging studies In one dose-ranging study, 354 patients (HbA1c 7.5%–10.0%, baseline average 8.4%) were randomized to vildagliptin 50 mg qd (n = 88), 50 mg bid (n = 83), or 100 mg qd (n = 91) or to placebo (n = 92) for 24 weeks (Pi-Sunyer 2007). Place...